Not Applicable
The present invention generally relates to field effect transistors. More specifically, the present invention relates to one dimensional and two dimensional field effect transistors.
The sequencing of Nucleic Acids, such as deoxyribonucleic acid (DNA), is a fundamental part of biological discovery. Such detection is useful for a variety of purposes and is often used in scientific research as well as medical advancement. For instance, the genomics and bioinformatics fields are concerned with the application of information technology and computer science to the field of molecular biology. In particular, bioinformatics techniques can be applied to process and analyze various genomic data, such as from an individual so as to determine qualitative and quantitative information about that data that can then be used by various practitioners in the development of diagnostic, prophylactic, and/or therapeutic methods for detecting, preventing or at least ameliorating diseased states, and thus, improving the safety, quality, and effectiveness of health care. The need for such diagnostic, therapeutic, and prophylactic advancements has led to a high demand for low-cost sequencing, which in turn has driven the development of high-throughput sequencing, termed as Next generation sequencing (NGS).
Generally, the approach to DNA analysis, such as for genetic diagnostics and/or sequencing, involves nucleic acid hybridization and detection. For example, various typical hybridization and detection approaches include the following steps. For genetic analysis, an RNA or DNA sample of a subject to be analyzed may be isolated and immobilized on a substrate, a probe of a known genetic sequence, e.g., a disease marker, may be labeled and washed across the substrate. If the disease marker is present, a binding event will occur, e.g., hybridization, and because the probe has been labeled the hybridization event may either be or not be detected thereby indicating the presence or absence of the disease marker in the subject's sample.
For DNA sequencing, first, an unknown nucleic acid sequence to be identified, e.g., a single-stranded sequence of DNA of a subject, is isolated, amplified, and immobilized on a substrate. Next, a known nucleic acid labeled with an identifiable tag is contacted with the unknown nucleic acid sequence in the presence of a polymerase. When hybridization occurs, the labeled nucleic acid binds to its complementary base in the unknown sequence immobilized on the surface of the substrate. The binding event can then be detected, e.g., optically or electrically. These steps are then repeated until the entire DNA sample has been completely sequenced. Typically, these steps are performed by a Next Gen Sequencer wherein thousands to millions of sequences may concurrently be produced in the next-generation sequencing process.
For example, a central challenge in DNA sequencing is assembling full-length genomic sequences, e.g., chromosomal sequences, from a sample of genetic material and/or mapping and aligning sample sequence fragments to a reference genome, yielding sequence data in a format that can be compared to a reference genomic sequence such as to determine the variants in the sampled full-length genomic sequences. In particular, the methods employed in sequencing protocols do not produce full-length chromosomal sequences of the sample DNA.
Rather, sequence fragments, typically from 100-1,000 nucleotides in length, are produced without any indication as to where in the genome they align. Therefore, in order to generate full length chromosomal genomic constructs, or determine variants with respect to a reference genomic sequence, these fragments of DNA sequences need to be mapped, aligned, merged, and/or compared to a reference genomic sequence. Through such processes the variants of the sample genomic sequences from the reference genomic sequences may be determined.
However, as the human genome is comprised of approximately 3.1 billion base pairs, and as each sequence fragment is typically only from 100 to 500 to 1,000 nucleotides in length, the time and effort that goes into building such full length genomic sequences and determining the variants therein is quite extensive often requiring the use of several different computer resources applying several different algorithms over prolonged periods of time.
In a particular instance, thousands to millions of fragments or even billions of DNA sequences are generated, aligned, and merged in order to construct a genomic sequence that approximates a chromosome in length. A step in this process may include comparing the DNA fragments to a reference sequence to determine where in the genome the fragments align.
The genetic material must be pre-processed, so as to derive usable genetic sequence data. This preprocessing may be done manually or via an automated sequencer. Typically, preprocessing involves obtaining a biological sample from a subject, such as through venipuncture, hair, etc. and treating the sample to isolate the DNA therefrom. Once isolated the DNA may be denatured, strand separated, and/or portions of the DNA may then be multiplied, e.g., via polymerase chain reaction (PCR), so as to build a library of replicated strands that are now ready to be read, such as by an automated sequencer, which sequencer is configured to read the replicate strands, e.g., by synthesis, and thereby determine the nucleotide sequences that makes up the DNA. Further, in various instances, such as in building the library of replicated strands, it may be useful to provide for over-coverage when preprocessing a given portion of the DNA. To perform this over-coverage, e.g., using PCR, may require increased sample preparation resources and time, and therefore be more expensive, but it often gives an enhanced probability of the end result being more accurate.
Once the library of replicated strands has been generated they may be injected into an automated sequencer that may then read the strands, such as by synthesis, so as to determine the nucleotide sequences thereof. For instance, the replicated single stranded DNA may be attached to a glass bead and inserted into a test vessel, e.g., an array. All the necessary components for replicating its complementary strand, including labeled nucleotides, are also added to the vessel but in a sequential fashion. For example, all labeled “A”, “C”, “G”, and “T's” are added, either one at a time or all together to see which of the nucleotides is going to bind at position one. After each addition a light, e.g., a laser, is shone on the array. If the composition fluoresces then an image is produced indicating which nucleotide bound to the subject location. More particularly, where the nucleotides are added one at a time, if a binding event occurs, then its indicative fluorescence will be observed. If a binding event does not occur, the test vessel may be washed and the procedure repeated until the appropriate one of the four nucleotides binds to its complement at the subject location, and its indicative fluorescence is observed. Where all four nucleotides are added at the same time, each may be labeled with a different fluorescent indicator, and the nucleotide that binds to its complement at the subject position may be determined, such as by the color of its fluorescence. This greatly accelerates the synthesis process.
Once a binding event has occurred, the complex is then washed and the synthesis steps are repeated for position two. For example, a marked nucleotide “A” may be added to the mix to determine if the complement at the position is a “T”, and if so, all the sequences having that complement will bind to the labeled “T” and will therefore fluoresce, and the samples will all be washed. Where the binding happened the bound nucleotide is not washed away, and then this will be repeated for all nucleotides for all positions until all the over-sampled nucleic acid segments, e.g., reads, have been sequenced and the data collected. Alternatively, where all four nucleotides are added at the same time, each labeled with a different fluorescent indicator, only one nucleotide will bind to its complement at the subject position, and the others will be washed away, such that after the vessel has been washed, a laser may be shone on the vessel and which nucleotide bound to its complement may be determined, such as by the color of its fluorescence.
This continues until the entire strand has been replicated in the vessel. Usually a typical length of a sequence replicated in this manner is from about 100 to about 500 base pairs, such as between 150 to about 400 base pairs, including from about 200 to about 350 base pairs, such as about 250 base pairs to about 300 base pairs dependent on the sequencing protocol being employed. Further, the length of these segments may be predetermined, e.g., engineered, to accord with any particular sequencing machinery and/or protocol by which it is run. The end result is a readout, or read, that is comprised of a replicated DNA segment, e.g., from about 100 to about 1,000 nucleotides in length, that has been labeled in such a manner that every nucleotide in the sequence, e.g., read, is known because of its label. Hence, since the human genome is comprised of about 3.2 billion base pairs, and various known sequencing protocols usually result in labeled replicated sequences, e.g., reads, from about 100 or 101 bases to about 250 or about 300 or about 400 bases, the total amount of segments that need to be sequenced, and consequently the total number of reads generated, can be anywhere from about 10,000,000 to about 40,000,000, such as about 15,000,000 to about 30,000,000, dependent on how long the label replicated sequences are. Therefore, the sequencer may typically generate about 30,000,000 reads, such as where the read length is 100 nucleotides in length, so as to cover the genome once.
However, in part, due to the need for the use of optically detectable, e.g., fluorescent, labels in the sequencing reactions being performed, the required instrumentation for performing such high throughput sequencing is bulky, costly, and not portable. For this reason, a number of new approaches for direct, label-free detection of DNA sequencing have been proposed. For instance, among the new approaches are detection methods that are based on the use of various electronic analytic devices. Such direct electronic detection methods have several advantages over the typical NGS platform. For example, the detector may be incorporated in the substrate itself, such as employing a biosystem-on-a-chip device, such as a complementary metal oxide semiconductor device, “CMOS”. More particularly, in using a CMOS device in genetic detection, the output signal representative of a hybridization event can be directly acquired and processed on a microchip. In such an instance, automatic recognition is achievable in real time and at a lower cost than is currently achievable using NGS processing. Moreover, standard CMOS devices may be employed for such electronic detection making the process simple, inexpensive, and portable.
Particularly, in order for next-generation sequencing to become widely used as a diagnostic in the healthcare industry, sequencing instrumentation will need to be mass produced with a high degree of quality and economy. One way to achieve this is to recast DNA sequencing in a format that fully leverages the manufacturing base created for computer chips, such as complementary metal-oxide semiconductor (CMOS) chip fabrication, which is the current pinnacle of large scale, high quality, low-cost manufacturing of high technology. To achieve this, ideally the entire sensory apparatus of the sequencer could be embodied in a standard semiconductor chip, manufactured in the same fab facilities used for logic and memory chips. Recently, such a sequencing chip, and the associated sequencing platform, has been developed and commercialized by Ion Torrent, a division of Thermo-Fisher, Inc. The promise of this idea has not been realized commercially due to the fundamental limits of applying a metal oxide semiconductor field effect transistor, or MOSFET, as a bio sensor. When a MOSFET is used in solution as a biosensor, it is referred to as an ISFET. A particular limitation includes a lack of sensor sensitivity and signal to noise characteristics as the semiconductor node scales down to lower geometries of the transistor (gate length).
More particularly, a field effect transistor, FET, typically includes a gate, a channel region connecting source and drain electrodes, and an insulating barrier separating the gate from the channel. The operation of a conventional FET relies on the control of the channel conductivity, and thus the drain current, by a voltage, VGS, applied between the gate and source. For high-speed applications, and for the purposes of increasing sensor sensitivity, FETs should respond quickly to variations in VGS. However, this requires short gates and fast carriers in the channel. Unfortunately, FETs with short gates frequently suffer from degraded electrostatics and other problems (collectively known as short channel effects), such as threshold-voltage roll-off, drain-induced barrier lowering, and impaired drain-current saturation, which results in a decrease in sensor sensitivity. Nevertheless, scaling theory predicts that a FET with a thin barrier and a thin gate-controlled region (measured in the vertical direction) will be robust against short-channel effects down to very short gate lengths (measured in the horizontal direction).
Accordingly, the possibility of having channels that are very thin in the vertical dimension would allow for high-speed transmission of carriers as well as for increased sensor sensitivity and accuracy. What is needed, therefore, is a FET device that is configured in such a manner as to include a shorter gate than is currently achievable in present FET applications. A solution that includes such a FET device designed for use in biological applications, such as for nucleic acid sequencing and/or genetic diagnostics would especially be beneficial.
The present invention is a chemically-sensitive field-effect transistor that solves many of the current problems associated with nucleic acid sequencing and genetic diagnostics.
One aspect of the present invention is a chemically-sensitive field effect transistor. The chemically-sensitive field effect transistor comprises an integrated circuit structure comprising a conductive source and a conductive drain and a channel. The channel extends from the conductive source to the conductive drain. The channel is composed of a one-dimensional transistor material or a two-dimensional transistor material. An I-V curve or an I-Vg curve is shifted in response to a chemical reaction occurring on or near the chemically-sensitive field effect transistor.
Another aspect of the present invention is a bio-sensor. The bio-sensor includes a semiconductor structure comprising a conductive source and a conductive drain, a 2D material channel (e.g. a graphene channel) or a 1D material channel (e.g. a Carbon NanoTube (CNT)) extending from the source to the drain and a well structure positioned on or over a portion of an exterior surface or topmost portion of the channel. The 1D or 2D material comprising the channel may be covered by a dielectric layer or may have no covering such that the well structure defines an opening allowing for direct contact with the either the dielectric layer or the 1D or 2D material channel. An I-Vg curve is shifted in response to detection of a biological compound.
Yet another aspect of the present invention is a 1D or 2D material field effect transistor such as a graphene field effect transistor or GFET. The GFET includes a structure comprising a conductive source, a conductive drain, and a graphene channel extending from the source to the drain. An I-Vg curve is shifted in response to a chemical reaction occurring on the graphene field effect transistor.
Yet another aspect of the present invention is a chemically-sensitive field effect transistor comprising an integrated circuit structure, a channel and an oxide layer. The integrated circuit structure comprises a conductive source and a conductive drain. The channel extends from the conductive source to the conductive drain. The channel is composed of a one-dimensional transistor material or a two-dimensional transistor material. The oxide layer is disposed over the channel. The I-V curve or an I-Vg curve is shifted in response to a chemical reaction occurring over or near the chemically-sensitive field effect transistor.
Yet another aspect of the present invention is a bio-sensor comprising a complementary metal-oxide-semiconductor (“CMOS”) structure, a graphene channel, an oxide layer, and a well structure. The CMOS structure comprises a damascene copper source and a damascene copper drain. The graphene channel extends from the source to the drain. The oxide layer is disposed over the graphene channel and has a thickness of 50 nanometers or less. The well structure is positioned over a portion of an exterior surface of the oxide layer. The well structure defines an opening allowing for direct contact with the oxide layer. An I-V or I-Vg curve is shifted in response to detection of a biological compound.
Yet another aspect of the present invention is a graphene field effect transistor comprising a CMOS structure, a graphene channel, an oxide layer, and a well structure. The CMOS structure comprises a copper source and a copper drain. The graphene channel extends from the source to the drain. The oxide layer is disposed over the graphene channel and has a thickness of 50 nanometers or less. The well structure is positioned over a portion of an exterior surface of the oxide layer. The well structure defines an opening allowing for direct contact with the oxide layer. An I-V or I-Vg curve is shifted in response to detection of a biological compound.
Having briefly described the present invention, the above and further objects, features and advantages thereof will be recognized by those skilled in the pertinent art from the following detailed description of the invention when taken in conjunction with the accompanying drawings.
As shown in
As shown in
As shown in
The channel 33 overlies a lower dielectric layer 37. SiO2 is a common dielectric used in semiconductor fabrication and can be used for this purpose. Alternatively other materials may be chosen that due to their structure allow the chemically-sensitive FET to operate at a high level (e.g. have enhanced mobility in the channel). In a preferred embodiment where the channel 33 is comprised of graphene the lower dielectric layer 37 is comprised of hexagonal boron nitride (hBN). Since both hBN and graphene have a hexagonal crystal lattice structure with very similar lattice spacing—the hBN does not distort the graphene lattice—thus allowing for higher carrier mobility in the graphene.
The channel 33 is preferably composed of a one-dimensional transistor material or a two-dimensional transistor material. In a preferred embodiment the two-dimensional material is graphene, as shown
Graphene is a two-dimensional mono layer of carbon atoms that form a lattice structure. The molecular structure of graphene, however, is very unique in that each carbon atom shares one of its four free valence electrons with three of its adjacent and planar carbon atoms such that each of the three planar carbon atoms is orientated at about a 120° with respect to the other three carbon atoms. This orientation gives graphene a honeycomb, lattice structure. Additionally, the fourth valence electron forms a pi bond, perpendicular to the three planar sigma-bonded carbon atoms, which is responsible for the unique electronic characteristics of graphene.
A single-layer graphene is a two-dimensional material. Its lattice structure forms regular hexagons with a carbon atom at each vertex. The bond length between adjacent carbon atoms is about 1.42 Å and the lattice constant is about 2.46 Å. This structure gives graphene two important characteristics: it makes graphene a semimetal (no bandgap) and it promotes rapid charge transport (mobility and high-field transport) at room temperature. Hence, in various instances, a graphene FET (G-FET or GFET used interchangeably), as herein described may perform better as a biological sensor then a typical CMOS-FET device. For instance, with respect to hybridization detection and/or sequencing, a traditional MOSFET transistor may have fundamental limitations in its sensitivity (due to channel thickness and intervening insulating layers), whereas a GFET has a single atom thickness channel that can be in direct contact or very close proximity with a chemical reaction zone. Furthermore graphene (or other 1D or 2D transistors) has a much higher carrier mobility than the doped silicon used in a MOSFET or IS_FET. This gives the herein disclosed GFETs increased sensitivity to and faster detection of chemical reactions.
As shown in
Preferably, a well structure 38 is positioned on or over a portion of an exterior surface of the analyte-sensitive dielectric layer 35 which in turn is on or over the channel 33 of a sensor 31, and the well structure defines an opening allowing for direct contact with the analyte-sensitive dielectric layer 35. The well structure 38 is preferably composed of an insulator material. The insulator material for the well structure is preferably an inorganic material, such as silicon oxide or silicon nitride. Alternatively, the insulator material for the well structure is an organic material such as a polyimide, a benzocyclobutene (“BCB”) material, or other like materials. If an organic material is used it is preferably a photosensitive material so that it can be photo-imaged and developed directly without the need for a photoresist material. The size (diameter or equivalent width), shape and depth of the well must be matched to the size range of microbeads carrying DNA template strands. It is preferred that the well geometry only allows the possibility for one bead to be entrapped in the well.
As shown in
As shown in
As shown in
Accordingly, when using the device for sequencing a nucleic acid sample, the target nucleic acid sample may be coupled to or in proximity with the graphene coated surface of the reaction zone. This template sequence may then be sequenced and/or analyzed by performing one or more of the following steps. For example, a primer, and/or a polymerase, e.g., an RNA and/or DNA polymerase, and/or one or more substrates, e.g. deoxynucleotide triphosphates dATP, dGTP, dCTP, and dTTP, may be added, e.g., sequentially, to the reaction chamber, such as after the hybridization reaction begins so as to induce an elongation reaction. Once the appropriate substrate hybridizes to its complement in the template sequence, there will be a concomitant change in the individual electrical characteristic voltage, e.g., the source-drain voltage (Vsd), measured as a result of the new local gating effect.
Hence, for every elongation reaction with the appropriate, e.g., complementary, substrate there will be a change in the characteristic voltage. For instance, as described herein, a field-effect device for nucleic acid sequencing and/or gene detection is disposed in a sample chamber of a flow cell, and a sample solution, e.g., containing a polymerase and one or more substrates, may be introduced to the sample solution chamber. In various embodiments, a reference electrode may be disposed upstream, downstream or in fluid contact with the field-effect device and/or the source and/or drain may themselves serve as electrodes, such as for hybridization detection, and gate voltage may be applied whenever needed.
Particularly, in an exemplary elongation reaction, polynucleotides are synthesized if the added substrate is complementary to the base sequence of the target DNA primer and/or template. If the added substrate is not complementary to the next available base sequence, hybridization does not occur and there is no elongation. Since nucleic acids, such as DNAs and RNAs, have a negative charge in aqueous solutions, hybridization resulting in elongation can be incrementally determined by the change in the charge density in the reaction chamber or well 38. And because the substrates are added sequentially, it can readily be determined which nucleotide bound to the template thereby facilitating the elongation reaction. Accordingly, as a result of elongation, the negative charge on the graphene gate surface, insulating film surface, and/or the sidewall surface of the reaction chamber will be increased. This increase may then be detected, such as a change in the gate-source voltage, as described in detail herein. By determining the addition of which substrate resulted in a signal of change in gate-source voltage, the base sequence identity of the target nucleic acid can be determined and/or analyzed.
More specifically, the field-effect transistor, such as for nucleic acid elongation and/or hybridization detection, may be associated with a buffered solution that is added to the reaction chamber, which can then be used to determine if an elongation reaction has taken place. Particularly, once the template is associated with the substrate, the reaction mixture containing a polymerase, e.g., a Taq polymerase, and a first nucleic acid substrate, e.g., a dATP, is added to the buffer solution to carry out the elongation reaction on or over the analyte-sensitive dielectric layer 35 or the graphene channel 33 coated insulating film of the reaction chamber surface. If the dATP is a complement to the next available reaction site in the isolated template a binding event, e.g., a hybridization reaction, will occur and the antisense strand of the growing sequence will be elongated, and detected by the GFET transistor.
For example, if adenine (A) is complementary to the base thymine (T) on the target template adjacent to the 3′-terminus of the nucleic acid template, an elongation reaction occurs, resulting in synthesis of one adenine. In such instance, the enzyme, Taq DNA polymerase, and the substrate may be washed away from the channel portion 33 and reaction chamber 38, and a buffer solution, e.g., a phosphoric acid buffer solution, e.g., having a pH of about 6, may be introduced on or over the graphene channel surface 33 or the analyte-sensitive dielectric layer 39 to measure changes in the source-drain voltage. If hybridization has occurred there will be a change in the source-drain voltage and it will be detected. However, if the dATP is not a match, there will be no hybridization, and if no hybridization, there will be no elongation. Consequently, a second reaction mixture containing another, different nucleotide substrate, e.g., dCTP and the enzyme polymerase, and the like will be added to the reaction chamber or well 38 under conditions suitable for hybridization, which if it occurs will be detected by the GFET. If not, then the steps will be repeated with the next substrate. These steps may be repeated until the nucleic acid sample has been completely sequenced. In various instances, the temperature within the reaction chamber may be controlled, for instance, it may be set to 74° C., such as by using a temperature sensor and/or a heater integrated in the field-effect device.
Consequently, if a hybridization reaction takes place there will be a resultant change to the threshold voltage, which will be increased, e.g., by 4 mV, from before the elongation reaction. The shift of the threshold voltage in the positive direction indicates that a negative charge was generated on or over the graphene channel surface 33. It can be understood from this that synthesis of one base caused by the elongation reaction was detectable as a change in threshold voltage. A second elongation reaction may then take place and be repeated until the entire target nucleic acid has been sequenced.
More particularly, in such a configuration as represented in the figures, the drain current of the transistor may be modulated by the electrical charge carried by the nucleotide molecules involved in the hybridization and/or sequencing reactions. For example, after a binding event, the charge in the reaction zone increases resulting in a change in the output current that may be measured. Such a measurement may be made in accordance with the following equation:
Such as where CC represents the current at the control capacitor, and CF represents the current at the parasitic capacitor. VTHF represents the effective threshold voltage of the transistor (Dirac point), and VTH0 represents the native threshold voltage (original Dirac point). Q0 represents the electric charge initially trapped in the floating gate, and QDNA represents the total charge of hybridization complex.
For instance, a nucleic acid from a sample to be sequenced or representative of a probe to be targeted may be immobilized on the bottom surface or the sidewall of the sample solution well chamber 38. A Taq DNA polymerase and a nucleotide substrate may then be introduced to the sample solution chamber to induce an elongation reaction. As a result, DNAs may be synthesized along the surface in the vertical or lateral direction, e.g., in parallel to the surface of the graphene coated channel surfaces. In such an instance, as the source-drain current vs gate voltage characteristic changes by the electrostatic interaction with the charged particles (electrons) in the well, and the synthesis of the DNA is in the direction that is transverse or parallel to the graphene channel surface, this keeps the distance between the DNA and the electrons constant, thereby helping to maintain a constant electrostatic interaction. Thus, the base sequence of a template nucleic acid having a large base length can be sequenced and/or analyzed. In other embodiments, a nucleic acid probe may be immobilized on the surface of the reaction zone, as described above, and used in a hybridization reaction so as to detect genetic variation and/or the presence of a genetic disease.
In various instances, in order to conduct parallel analysis of a plurality of nucleic acid templates, the number of the transistors may be equal to or higher than the number and/or types of DNAs to be sequenced and/or analyzed. In certain instances, each nucleic acid template or probe may be an oligonucleotide or a fragment of DNA or RNA that may be constituted from about 100 to about 1000 bases, such as from 200 to about 800 bases, for instance, from about 300 or about 500 bases to about 600 or 700 bases or more or somewhere in between. However, in various instances, a fragment of nucleic acid having 100 bases or fewer may also be used.
Additionally, as indicated above, the device 10 may also be used in various different DNA/RNA hybridization reactions, such as for the purpose of determining a genetic variation and/or for detecting the presence of a genetic marker for a disease. In such an instance, a nucleic acid probe may be coupled to a bottom or side graphene coated or analyte-sensitive dielectric layer coated surface of the reaction chamber or well 38, per above. As indicated, the probe may be of any suitable length but in various instances from about 5 or 10 to about 1000 bases, such as from 20 or about 50 to about 700 or about 800 bases, for instance, from about 100 or about 200 bases to about 300 bases including about 400 or about 500 bases to about 600 or 700 bases or more or somewhere in between.
For instance, in one exemplary instance, a nucleic acid probe containing about 10 to 15 bases coding for a gene sequence of interest that has been previously amplified, such as by polymerase chain reaction (PCR), may be immobilized on the channel, analyte-sensitive dielectric layer or side surface of the reaction chamber 38 of the field-effect transistor. For example, once isolated and amplified, the base of the template may be modified so as to be attached to the graphene or analyte-sensitive dielectric coated surface, and/or may be coupled to a secondary substrate, such as a glass or plastic bead that has been chemically treated so as to be coupled therewith. Once immobilized, the reaction chamber containing the probes, either on a secondary substrate or directly coupled with a chamber surface, may be reacted with a sample solution containing a number genes including a target gene of interest to be measured such that when a nucleic acid probe having a complementary base sequence to the target gene is immobilized on the gate, gate insulating film or the sidewall surface of the sample solution well structure, or on a secondary substrate immobilized within the reaction chamber of the field-effect device for gene detection, the target gene hybridizes with the nucleic acid probe under appropriate reaction conditions and the target gene and the nucleic acid probe form a double strand, the result of which hybridization reaction may be detected.
A GFET array sets forth a two dimensional GFET sensor array chip that in this instance is based on a column and row design, although other designs are also possible. The system further includes a row and column decoder, as well as circuitry for performing the requisite sensing, detecting, and processing so as to measure the sensory data. Hence, also included is sensing, measurement, and other associated readout data.
Accordingly, in various instances, a one or two-dimensional GFET array, as described herein, may be fabricated on a microchip in accordance with the methods herein disclosed. In various instances, the array chip may include a number of GFET sensors that may be arranged in columns and/or rows. A typical number of sensors may include GFET sensor elements, described herein as “sensors,” that may be arranged in a 16 sensor by 16 sensor column/row array configuration. As depicted, the array includes two columns, but typically may include sixteen columns, arranged side by side, where each column includes 16 rows. Particularly, each column of the array includes up to 16 sensors. Each column may be configured so as to include a current source ISOURCE that may be shared by all sensors of the column. However, in various other embodiments, each sensor may have its own current source, or the array itself may have a single current source. Additionally, each GFET sensor may include a GFET, as described above, having an electrically coupled source and/or drain and/or body, and may further include one or more switches, such as a plurality of switches S1 and S2 that may be configured so as to be responsive to one of the up to sixteen row select signals (RSEL, and it's complements). More particularly, a row select signal and its complement may be generated simultaneously to “enable” or select a given sensor of the selected column, and such signal pairs may be generated in some sequence to successively enable different sensors of the column, e.g., together or one at a time, such as sequentially. Other architectures may be employed to address the sensors—including architectures that may only require one access transistor per sensor.
A row decoder may also be provided as part of the system. In such an instance, the row decoder may be configured so as to provide up to sixteen pairs of complementary row select signals, wherein each pair of row select signals may be adapted so as to simultaneously or sequentially enable one sensor in each column so as to provide a set of column output signals from the array, e.g., based on the respective source voltages VSa through VSb, etc. of the enabled row of GFETs. The row decoder may be implemented as a conventional four-to-sixteen decoder (e.g., a four-bit binary input ROW1-ROW4 to select one of 24 outputs). The set of column output signals VSa through VSb for an enabled row of the array is applied to switching logic, which may be configured to include up to sixteen transmission gates Sa through Sb (e.g., one transmission gate for each output signal).
As above, each transmission gate of the switching logic may be implemented using an n-channel or p-channel MOSFET, in a bottom or top gate configuration, or both to ensure a sufficient dynamic range for each of the output signals VSa through VSb. The column decoder, like the row decoder, may be implemented as a conventional four-to-sixteen decoder and may be controlled via the four-bit binary input COL1-COL4 to enable one of the transmission gates Sa through Sb of the switching logic at any given time, so as to provide a single output signal VS from the switching logic. This output signal VS may be applied to a 10-bit analog to digital converter (ADC) to provide a digital representation D1-D10 of the output signal VS corresponding to a given sensor of the array.
As noted earlier, individual GFETs and arrays of GFETs such as those discussed above may be employed as sensing devices in a variety of applications involving chemistry and biology. In particular, such GFETs may be employed as pH sensors in various processes involving nucleic acids such as DNA. In general, the development of rapid and sensitive nucleic acid hybridization and sequencing methods, as herein described, e.g., utilizing automated DNA sequencers, may significantly advance the understanding of biology.
It should be noted, that with respect to the various arrays disclosed herein according to various embodiments of the present disclosure may be fabricated according to conventional CMOS fabrication techniques, as described above, as well as modified CMOS fabrication techniques (e.g., to facilitate realization of various functional aspects of the GFET arrays discussed herein, such as additional deposition of graphene and/or other materials, process steps to mitigate trapped charge, etc.) and other semiconductor fabrication techniques beyond those conventionally employed in typical CMOS fabrication (e.g BiCMOS). Additionally, various lithography techniques may be employed as part of an array fabrication process. For example, in one exemplary implementation, a lithography technique may be employed in which appropriately designed blocks are “stitched” together by overlapping the edges of a step and repeat lithography exposures on a wafer substrate by approximately 0.2 micrometers. In a single exposure, the maximum die size typically is approximately 21 millimeters by 21 millimeters. By selectively exposing different blocks (sides, top & bottoms, core, etc.) very large chips can be defined on a wafer (up to a maximum, in the extreme, of one chip per wafer, commonly referred to as “wafer scale integration”).
In one embodiment, the array includes 512 columns with corresponding column bias/readout circuitry (one for each column), wherein each column includes geometrically square sensors, each having a size of approximately 9 micrometers by 9 micrometers (e.g., the array may be up to 512 columns by 512 rows). In various instances, the entire array (including sensors together with associated row and column select circuitry and column bias/readout circuitry) may be fabricated on a semiconductor die as an application specific integrated circuit (ASIC), structured ASIC, or as a field programmable gate array, such as having dimensions of approximately 7 millimeters by 7 millimeters.
Various power supply and bias voltages useful for array operation are provided to the array via electrical connections (e.g., pins, metal pads) and labeled for simplicity in block as “supply and bias connections.” The array may also include a row select shift register, one or more, e.g., two sets of column select shift registers, and one or more, e.g., two, output drivers, which output drivers are configured to provide two parallel output signals from the array, Vouta and Voutb, representing sensor measurements. The various power supply and bias voltages, control signals for the row and column shift registers, and control signals for the column bias/readout circuitry may be provided by an array controller, which controller may also read the output signals Vouta and Voutb (and other optional status/diagnostic signals) from the array.
Configuring the array such that multiple regions (e.g., multiple columns) of the array may be read at the same time via multiple parallel array outputs (e.g., Vouta and Voutb) facilitates increased data acquisition rates.
It should be noted that, in various embodiments of the array, one or more of the columns, e.g., the first and last columns, as well as the first and/or last sensors of each of the columns may be configured as “reference” or “dummy” sensors. For instance, the dummy sensors of an array, e.g., the topmost metal layer of each dummy sensor may be tied to the same metal layer of other dummy sensors and may be made accessible as a terminal of the chip, which in turn may be coupled to a reference voltage VREF. Such reference voltage VREF may be applied to the bias/readout circuitry of respective columns of the array. In some exemplary implementations, preliminary test/evaluation data may be acquired from the array based on applying the reference voltage VREF and selecting and reading out dummy sensors, and/or reading out columns based on the direct application of VREF to respective column buffers (e.g., via the CAL signal), to facilitate offset determination (e.g., sensor-to-sensor and column-to-column variances) and array calibration. The calibration data can be stored for each sensor location either just prior to a sequencing session, or preferentially at the end of the device manufacturing process. The calibration data can be stored on-chip in non-volatile memory.
A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Patent Publication Number 20140371110 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Patent Publication Number 20140309944 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Patent Publication Number 20140236490 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Pat. No. 9,014,989 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in U.S. Provisional Application No. 61/826,381, titled System and Method for Computation Geneomic Pipeline, filed May 22, 2013, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in U.S. Patent Publication Number 20150339437, for Dynamic Genome Reference Generation For Improved NGS Accuracy And Reproducibility, filed Feb. 24, 2015, which is hereby incorporated by reference in its entirety. A description of a GFET is set forth in van Rooyen, U.S. Provisional Patent Application No. 62/094,016, filed on Dec. 18, 2014, for Graphene FET Devices, Systems, And Methods Of Using The Same For Sequencing Nucleic Acids, which is hereby incorporated by reference in its entirety. A description of a GFET is set forth in Hoffman et al., U.S. Provisional Patent Application No. 62/130,594, filed on Mar. 9, 2015, for Chemically Sensitive Field Effect Transistor, which is hereby incorporated by reference in its entirety. A more detailed description of a GFET is set forth in Hoffman et al., U.S. Provisional Patent Application No. 62/206,228, filed on Aug. 17, 2015, for Chemically Sensitive Field Effect Transistor, which is hereby incorporated by reference in its entirety. A more detailed description of a GFET is set forth in Hoffman et al., U.S. Provisional Patent Application No. 62/199,987, filed on Aug. 1, 2015, for Chemically Sensitive Field Effect Transistor, which is hereby incorporated by reference in its entirety.
From the foregoing it is believed that those skilled in the pertinent art will recognize the meritorious advancement of this invention and will readily understand that while the present invention has been described in association with a preferred embodiment thereof, and other embodiments illustrated in the accompanying drawings, numerous changes modification and substitutions of equivalents may be made therein without departing from the spirit and scope of this invention which is intended to be unlimited by the foregoing except as may appear in the following appended claim. Therefore, the embodiments of the invention in which an exclusive property or privilege is claimed are defined in the following appended claims.
The present application claims priority to U.S. Provisional Patent Application No. 62/206,228, filed on Aug. 17, 2015, U.S. Provisional Patent Application No. 62/199,987, filed on Aug. 1, 2015, U.S. Provisional Patent Application No. 62/130,594, filed on Mar. 9, 2015, and U.S. Provisional Patent Application No. 62/094,016, filed on Dec. 18, 2014, all of which are hereby incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3377893 | Shorb | Apr 1968 | A |
3466874 | Holl | Sep 1969 | A |
3564151 | Shlesinger, Jr. | Feb 1971 | A |
3605428 | Smith et al. | Sep 1971 | A |
3691109 | Larsen | Sep 1972 | A |
3772069 | Daniel | Nov 1973 | A |
3828094 | Widdig et al. | Aug 1974 | A |
3892139 | Harris | Jul 1975 | A |
3931401 | Prasad et al. | Jan 1976 | A |
5397863 | Afzali-Ardakani et al. | Mar 1995 | A |
5556899 | Afzali-Ardakani et al. | Sep 1996 | A |
5571852 | Afzali-Ardakani et al. | Nov 1996 | A |
5591285 | Afzali-Ardakani et al. | Jan 1997 | A |
5639660 | Kinet et al. | Jun 1997 | A |
5701256 | Marr et al. | Dec 1997 | A |
5958784 | Benner | Sep 1999 | A |
6001611 | Will | Dec 1999 | A |
6377893 | Benner | Apr 2002 | B1 |
6466874 | Eisenberg et al. | Oct 2002 | B1 |
6564151 | Pellegrini et al. | May 2003 | B1 |
6605428 | Kilger et al. | Aug 2003 | B2 |
6691109 | Bjornson et al. | Feb 2004 | B2 |
6772069 | Eisenberg et al. | Aug 2004 | B1 |
6828094 | Kilger et al. | Dec 2004 | B2 |
6892139 | Eisenberg et al. | May 2005 | B2 |
6931401 | Gibson et al. | Aug 2005 | B2 |
7008764 | Honold et al. | Mar 2006 | B1 |
7247877 | Hakey et al. | Jul 2007 | B2 |
7253431 | Afzali-Ardakani et al. | Aug 2007 | B2 |
7333980 | Bjornson et al. | Feb 2008 | B2 |
7462468 | Williams et al. | Dec 2008 | B1 |
7484423 | Hakey et al. | Feb 2009 | B2 |
7492015 | Chen et al. | Feb 2009 | B2 |
7504132 | Afzali-Ardakani et al. | Mar 2009 | B2 |
7514063 | Tulevski et al. | Apr 2009 | B1 |
7544546 | Afzali-Ardakani et al. | Jun 2009 | B2 |
7612270 | Zhu | Nov 2009 | B1 |
7670810 | Gunderson et al. | Mar 2010 | B2 |
7727505 | Afazali-Ardakani et al. | Jun 2010 | B2 |
7732119 | Afzali-Ardakani et al. | Jun 2010 | B2 |
7745118 | Green et al. | Jun 2010 | B2 |
7750908 | Kincaid et al. | Jul 2010 | B2 |
7761462 | Bjornson et al. | Jul 2010 | B2 |
7771695 | Afzali-Ardakani et al. | Aug 2010 | B2 |
7855133 | Afzali-Ardakani et al. | Dec 2010 | B2 |
7867469 | Afzali-Ardakani et al. | Jan 2011 | B2 |
7879307 | Afzali-Ardakani et al. | Feb 2011 | B2 |
7883685 | Afzali-Ardakani et al. | Feb 2011 | B1 |
7888528 | Afzali-Ardakani et al. | Feb 2011 | B2 |
7917299 | Buhler et al. | Mar 2011 | B2 |
7932029 | Lok | Apr 2011 | B1 |
7948015 | Rothberg et al. | May 2011 | B2 |
7951424 | Afzali-Ardakani et al. | May 2011 | B2 |
7955585 | Afzali-Ardakani et al. | Jun 2011 | B2 |
7955931 | Appenzeller et al. | Jun 2011 | B2 |
7982274 | Afzali-Ardakani et al. | Jul 2011 | B2 |
7993842 | McKeman et al. | Aug 2011 | B2 |
8017934 | Appenzeller et al. | Sep 2011 | B2 |
8032305 | Shibuya | Oct 2011 | B2 |
8039334 | Furukawa et al. | Oct 2011 | B2 |
8039909 | Afzali-Ardakani et al. | Oct 2011 | B2 |
8057984 | Afzali-Ardakani et al. | Nov 2011 | B2 |
8084012 | Afzali-Ardakani et al. | Dec 2011 | B2 |
8095508 | Chamberlain et al. | Jan 2012 | B2 |
8124463 | Chen et al. | Feb 2012 | B2 |
8138102 | Afzali-Ardakani et al. | Mar 2012 | B2 |
8138491 | Appenzeller et al. | Mar 2012 | B2 |
8138492 | Afzali-Ardakani et al. | Mar 2012 | B2 |
8143030 | Maxham et al. | Mar 2012 | B2 |
8153375 | Travers et al. | Apr 2012 | B2 |
8182989 | Bignell et al. | May 2012 | B2 |
8182993 | Tomaney et al. | May 2012 | B2 |
8209130 | Kennedy et al. | Jun 2012 | B1 |
8211735 | Graham et al. | Jul 2012 | B2 |
8211741 | Appenzeller et al. | Jul 2012 | B2 |
8217433 | Fife | Jul 2012 | B1 |
8227171 | Afzali-Ardakani et al. | Jul 2012 | B2 |
8244479 | Kain et al. | Aug 2012 | B2 |
8283453 | Afzali-Ardakani et al. | Oct 2012 | B2 |
8283703 | Solomon | Oct 2012 | B2 |
8293607 | Afzali-Ardakani et al. | Oct 2012 | B2 |
8296075 | Den Hartog | Oct 2012 | B2 |
8306757 | Rothberg et al. | Nov 2012 | B2 |
8309330 | Travers et al. | Nov 2012 | B2 |
8329400 | Lok | Dec 2012 | B2 |
8383345 | Shendure et al. | Feb 2013 | B2 |
8383369 | Maxham et al. | Feb 2013 | B2 |
8394727 | Afzali-Ardakani et al. | Mar 2013 | B1 |
8395774 | Afzali et al. | Mar 2013 | B2 |
8445945 | Rothberg et al. | May 2013 | B2 |
8455193 | Travers et al. | Jun 2013 | B2 |
8455297 | Avouris et al. | Jun 2013 | B1 |
8455311 | Solomon | Jun 2013 | B2 |
8463555 | Zhang | Jun 2013 | B2 |
8465647 | Bol et al. | Jun 2013 | B2 |
8471249 | Chiu et al. | Jun 2013 | B2 |
8481413 | Afzali-Ardakani et al. | Jul 2013 | B2 |
8486630 | Pan et al. | Jul 2013 | B2 |
8491769 | Afzali-Ardakani et al. | Jul 2013 | B2 |
8492293 | Afzali-Ardakani et al. | Jul 2013 | B1 |
8492748 | Chang et al. | Jul 2013 | B2 |
8512458 | Holmes et al. | Aug 2013 | B2 |
8515682 | Buhler et al. | Aug 2013 | B2 |
8518829 | Dang et al. | Aug 2013 | B2 |
8524487 | Fife | Sep 2013 | B2 |
8535882 | Christians et al. | Sep 2013 | B2 |
8546246 | Lin et al. | Oct 2013 | B2 |
8554492 | Ahn et al. | Oct 2013 | B2 |
8557097 | Afzali-Ardakani et al. | Oct 2013 | B2 |
8558288 | Rothberg et al. | Oct 2013 | B2 |
8574892 | Su | Nov 2013 | B2 |
8587065 | Chen et al. | Nov 2013 | B2 |
8594951 | Homer | Nov 2013 | B2 |
8598569 | Afzali-Ardakani et al. | Dec 2013 | B2 |
8603792 | Nikiforov et al. | Dec 2013 | B2 |
8604559 | Afzali-Ardakani et al. | Dec 2013 | B2 |
8609481 | Franklin et al. | Dec 2013 | B1 |
8610989 | Avouris et al. | Dec 2013 | B2 |
8614436 | Solomon | Dec 2013 | B2 |
8617941 | Farmer et al. | Dec 2013 | B2 |
8620881 | Chamberlain et al. | Dec 2013 | B2 |
8628940 | Sorenson et al. | Jan 2014 | B2 |
8637374 | Appenzeller et al. | Jan 2014 | B2 |
8642432 | Afzali-Ardakani et al. | Feb 2014 | B2 |
8674412 | Franklin et al. | Mar 2014 | B2 |
8688388 | Dzakula et al. | Apr 2014 | B2 |
8698226 | Jain et al. | Apr 2014 | B2 |
8700341 | Rava et al. | Apr 2014 | B2 |
8716029 | Kim et al. | May 2014 | B1 |
8716597 | Mann et al. | May 2014 | B2 |
8725422 | Halpern et al. | May 2014 | B2 |
8738300 | Porreca et al. | May 2014 | B2 |
8741678 | Chen et al. | Jun 2014 | B2 |
8741751 | Cao et al. | Jun 2014 | B2 |
8741756 | Franklin et al. | Jun 2014 | B2 |
8751166 | Friedlander et al. | Jun 2014 | B2 |
8751452 | Chamberlain et al. | Jun 2014 | B2 |
8753816 | Rigatti et al. | Jun 2014 | B2 |
8753912 | Graham et al. | Jun 2014 | B2 |
8754393 | Cao et al. | Jun 2014 | B2 |
8765547 | Farmer et al. | Jul 2014 | B2 |
8766345 | Farmer et al. | Jul 2014 | B2 |
8772141 | Afzali-Ardakani et al. | Jul 2014 | B2 |
8772910 | Afzali-Ardakani et al. | Jul 2014 | B2 |
8779414 | Chang et al. | Jul 2014 | B2 |
8785262 | Farmer et al. | Jul 2014 | B2 |
8785911 | Chen et al. | Jul 2014 | B2 |
8786018 | Farmer et al. | Jul 2014 | B2 |
8795961 | Rank et al. | Aug 2014 | B2 |
8796642 | Boday et al. | Aug 2014 | B2 |
8796668 | Lin et al. | Aug 2014 | B2 |
8797059 | Boday et al. | Aug 2014 | B2 |
8803129 | Chang et al. | Aug 2014 | B2 |
8803131 | Lin et al. | Aug 2014 | B2 |
8803132 | Farmer et al. | Aug 2014 | B2 |
8805148 | Avouris et al. | Aug 2014 | B2 |
8809153 | Afzali-Ardakani et al. | Aug 2014 | B2 |
8809837 | Farmer et al. | Aug 2014 | B2 |
8816328 | Chang et al. | Aug 2014 | B2 |
8816787 | Jenkins et al. | Aug 2014 | B2 |
8828762 | Chu et al. | Sep 2014 | B2 |
8834967 | Afzali-Ardakani et al. | Sep 2014 | B2 |
8835686 | Afzali-Ardakani et al. | Sep 2014 | B2 |
8852342 | Dimitrakopoulos et al. | Oct 2014 | B2 |
8852985 | Cai et al. | Oct 2014 | B2 |
8853034 | Afzali-Ardakani et al. | Oct 2014 | B2 |
8859048 | Afzali-Ardakani et al. | Oct 2014 | B2 |
8859439 | Avouris et al. | Oct 2014 | B1 |
8877340 | Chu et al. | Nov 2014 | B2 |
8878193 | Avouris et al. | Nov 2014 | B2 |
8890116 | Chen et al. | Nov 2014 | B2 |
8890121 | Han et al. | Nov 2014 | B1 |
8895372 | Guo et al. | Nov 2014 | B2 |
8895417 | Afzali-Ardakani et al. | Nov 2014 | B2 |
8900538 | Abou-Kandil et al. | Dec 2014 | B2 |
8900918 | Avouris et al. | Dec 2014 | B2 |
8901680 | Cai et al. | Dec 2014 | B2 |
8901689 | Avouris et al. | Dec 2014 | B1 |
8911972 | Chaisson et al. | Dec 2014 | B2 |
8912525 | Afzali-Ardakani et al. | Dec 2014 | B2 |
8916451 | Bayram et al. | Dec 2014 | B2 |
8927057 | Bol et al. | Jan 2015 | B2 |
8932919 | Farmer et al. | Jan 2015 | B2 |
8936763 | Rothberg et al. | Jan 2015 | B2 |
8951727 | Jaramillo-Botero et al. | Feb 2015 | B2 |
8952258 | Plucinski et al. | Feb 2015 | B2 |
8957405 | Adkisson et al. | Feb 2015 | B2 |
8957463 | Afzali-Ardakani et al. | Feb 2015 | B2 |
8963215 | Afzali-Ardakani et al. | Feb 2015 | B2 |
8968582 | Franklin et al. | Mar 2015 | B2 |
8969090 | Sun et al. | Mar 2015 | B2 |
8969115 | Chen et al. | Mar 2015 | B2 |
8969118 | Afzali-Ardakani et al. | Mar 2015 | B2 |
8975095 | Han et al. | Mar 2015 | B2 |
8987740 | Avouris et al. | Mar 2015 | B2 |
9000499 | Franklin et al. | Apr 2015 | B2 |
9000594 | Ott et al. | Apr 2015 | B2 |
9014989 | McMillen et al. | Apr 2015 | B2 |
9017813 | El-Ashry et al. | Apr 2015 | B2 |
9029841 | Farmer et al. | May 2015 | B2 |
9040364 | Farmer et al. | May 2015 | B2 |
9045796 | Gunderson et al. | Jun 2015 | B2 |
9045842 | Han et al. | Jun 2015 | B2 |
9051611 | Christians et al. | Jun 2015 | B2 |
9059188 | Dimitrakopoulos et al. | Jun 2015 | B1 |
9062389 | Han et al. | Jun 2015 | B2 |
9064698 | Khakifirooz et al. | Jun 2015 | B1 |
9064776 | Lin et al. | Jun 2015 | B2 |
9064842 | Bol et al. | Jun 2015 | B2 |
9068221 | Merriman et al. | Jun 2015 | B2 |
9068936 | Guo et al. | Jun 2015 | B2 |
9076873 | Chen et al. | Jul 2015 | B2 |
9082856 | Chen et al. | Jul 2015 | B2 |
9085802 | Liu et al. | Jul 2015 | B2 |
9087691 | Zhu et al. | Jul 2015 | B2 |
9091648 | Afzali-Ardakani et al. | Jul 2015 | B2 |
9093507 | Cohen et al. | Jul 2015 | B2 |
9093631 | Davis | Jul 2015 | B2 |
9097658 | Afzali-Ardakani et al. | Aug 2015 | B2 |
9099542 | Franklin et al. | Aug 2015 | B2 |
9102118 | Afzali-Ardakani et al. | Aug 2015 | B2 |
9102540 | Afzali-Ardakani et al. | Aug 2015 | B2 |
9103776 | Afzali-Ardakani et al. | Aug 2015 | B2 |
9105702 | Franklin et al. | Aug 2015 | B2 |
9105853 | Afzali-Ardakani et al. | Aug 2015 | B2 |
9123454 | Franklin et al. | Sep 2015 | B2 |
9142471 | Abou-Kandil et al. | Sep 2015 | B2 |
9145295 | Peng | Sep 2015 | B2 |
9146209 | Johnson et al. | Sep 2015 | B2 |
9150918 | Turner et al. | Oct 2015 | B2 |
9157887 | Guo et al. | Oct 2015 | B2 |
9162883 | El-Ashry et al. | Oct 2015 | B2 |
9174413 | Avouris et al. | Nov 2015 | B2 |
9174414 | Avouris et al. | Nov 2015 | B2 |
9177688 | Bol et al. | Nov 2015 | B2 |
9179579 | Hada et al. | Nov 2015 | B2 |
9281305 | Yang | Mar 2016 | B1 |
9618474 | van Rooyen et al. | Apr 2017 | B2 |
20020164588 | Eisenberg et al. | Nov 2002 | A1 |
20020194173 | Bjornson et al. | Dec 2002 | A1 |
20030033279 | Gibson et al. | Feb 2003 | A1 |
20030200033 | Segal et al. | Oct 2003 | A1 |
20030224384 | Sayood et al. | Dec 2003 | A1 |
20030228618 | Levanon et al. | Dec 2003 | A1 |
20040072204 | Shibuya | Apr 2004 | A1 |
20040110227 | Levanon et al. | Jun 2004 | A1 |
20040142347 | Stockwell et al. | Jul 2004 | A1 |
20040143571 | Bjornson et al. | Jul 2004 | A1 |
20040152108 | Keith et al. | Aug 2004 | A1 |
20040241730 | Yakhini et al. | Dec 2004 | A1 |
20040248189 | Bulaj et al. | Dec 2004 | A1 |
20050009771 | Levanon et al. | Jan 2005 | A1 |
20050038609 | Benner | Feb 2005 | A1 |
20050039123 | Kuchinsky et al. | Feb 2005 | A1 |
20050107961 | Uemura et al. | May 2005 | A1 |
20050131649 | Larsen et al. | Jun 2005 | A1 |
20050188294 | Kuchinsky et al. | Aug 2005 | A1 |
20050197783 | Kuchinsky et al. | Sep 2005 | A1 |
20050240352 | Liang | Oct 2005 | A1 |
20060016699 | Kamahori et al. | Jan 2006 | A1 |
20060028471 | Kincaid et al. | Feb 2006 | A1 |
20060064247 | Yuan et al. | Mar 2006 | A1 |
20060100788 | Carrino et al. | May 2006 | A1 |
20060106545 | Balaji et al. | May 2006 | A1 |
20060141529 | Koleske et al. | Jun 2006 | A1 |
20060275794 | Carrino et al. | Dec 2006 | A1 |
20060294059 | Chamberlain et al. | Dec 2006 | A1 |
20070063304 | Matsumoto | Mar 2007 | A1 |
20070067108 | Buhler et al. | Mar 2007 | A1 |
20070088510 | Li et al. | Apr 2007 | A1 |
20070134692 | Valmeekam et al. | Jun 2007 | A1 |
20070138463 | Herlogsson et al. | Jun 2007 | A1 |
20070152335 | Chun | Jul 2007 | A1 |
20070196816 | Schwartz et al. | Aug 2007 | A1 |
20070232060 | Niu | Oct 2007 | A1 |
20070259337 | Hully et al. | Nov 2007 | A1 |
20070277036 | Chamberlain et al. | Nov 2007 | A1 |
20080035494 | Gomez et al. | Feb 2008 | A1 |
20080063566 | Matsumoto | Mar 2008 | A1 |
20080086274 | Chamberlain et al. | Apr 2008 | A1 |
20080104041 | Bjornson et al. | May 2008 | A1 |
20080154567 | Qiu et al. | Jun 2008 | A1 |
20080250016 | Farrar | Oct 2008 | A1 |
20080274912 | Johnson et al. | Nov 2008 | A1 |
20080283875 | Mukasa | Nov 2008 | A1 |
20090008629 | Matsumoto | Jan 2009 | A1 |
20090014757 | Takulapalli | Jan 2009 | A1 |
20090119313 | Pearce | May 2009 | A1 |
20090125248 | Shams et al. | May 2009 | A1 |
20090153130 | Shim et al. | Jun 2009 | A1 |
20090156431 | Lok | Jun 2009 | A1 |
20090171647 | Mannava et al. | Jul 2009 | A1 |
20090278556 | Man et al. | Nov 2009 | A1 |
20090292665 | Den Hartog | Nov 2009 | A1 |
20090325239 | Lok | Dec 2009 | A1 |
20100025660 | Jain et al. | Feb 2010 | A1 |
20100035254 | Williams | Feb 2010 | A1 |
20100069263 | Shendure et al. | Mar 2010 | A1 |
20100075309 | Maxham et al. | Mar 2010 | A1 |
20100075327 | Maxham et al. | Mar 2010 | A1 |
20100077267 | Perego et al. | Mar 2010 | A1 |
20100082805 | Orton et al. | Apr 2010 | A1 |
20100088040 | Johnson, Jr. | Apr 2010 | A1 |
20100105202 | Daamen | Apr 2010 | A1 |
20100121582 | Pan et al. | May 2010 | A1 |
20100176463 | Koizumi et al. | Jul 2010 | A1 |
20100227384 | Vann | Sep 2010 | A1 |
20100228496 | Leong et al. | Sep 2010 | A1 |
20100293167 | Biasci et al. | Nov 2010 | A1 |
20100304989 | Von Hoff et al. | Dec 2010 | A1 |
20100327847 | Leiber et al. | Dec 2010 | A1 |
20110003301 | Raymond et al. | Jan 2011 | A1 |
20110004413 | Carnevali et al. | Jan 2011 | A1 |
20110042673 | Yamabayashi | Feb 2011 | A1 |
20110098193 | Kingsmore et al. | Apr 2011 | A1 |
20110121273 | Jo | May 2011 | A1 |
20110177517 | Rava et al. | Jul 2011 | A1 |
20110195406 | Sorenson et al. | Aug 2011 | A1 |
20110201507 | Rava et al. | Aug 2011 | A1 |
20110210314 | Chung et al. | Sep 2011 | A1 |
20110212464 | Hagmann et al. | Sep 2011 | A1 |
20110224087 | Quake et al. | Sep 2011 | A1 |
20110227043 | Guo et al. | Sep 2011 | A1 |
20110230358 | Rava | Sep 2011 | A1 |
20110231446 | Buhler et al. | Sep 2011 | A1 |
20110237444 | Clancy et al. | Sep 2011 | A1 |
20110245085 | Rava et al. | Oct 2011 | A1 |
20110252008 | Chamberlain et al. | Oct 2011 | A1 |
20110257889 | Klammer et al. | Oct 2011 | A1 |
20110270533 | Zhang et al. | Nov 2011 | A1 |
20110281740 | Beechem et al. | Nov 2011 | A1 |
20110281768 | Travers et al. | Nov 2011 | A1 |
20110295514 | Breu et al. | Dec 2011 | A1 |
20110295858 | Ahn et al. | Dec 2011 | A1 |
20110295977 | Shibuya | Dec 2011 | A1 |
20110296543 | Chang et al. | Dec 2011 | A1 |
20120001615 | Levine | Jan 2012 | A1 |
20120010085 | Rava et al. | Jan 2012 | A1 |
20120011086 | Zhang et al. | Jan 2012 | A1 |
20120021918 | Bashir et al. | Jan 2012 | A1 |
20120046175 | Rodesch et al. | Feb 2012 | A1 |
20120046877 | Hyland et al. | Feb 2012 | A1 |
20120053845 | Bruestle et al. | Mar 2012 | A1 |
20120089339 | Ganeshalingam et al. | Apr 2012 | A1 |
20120094849 | Rava et al. | Apr 2012 | A1 |
20120095697 | Halpern et al. | Apr 2012 | A1 |
20120100548 | Rava et al. | Apr 2012 | A1 |
20120102041 | Park et al. | Apr 2012 | A1 |
20120109849 | Chamberlain et al. | May 2012 | A1 |
20120110316 | Chamberlain et al. | May 2012 | A1 |
20120116688 | Mishra et al. | May 2012 | A1 |
20120149582 | Rava et al. | Jun 2012 | A1 |
20120156677 | Bitinaite et al. | Jun 2012 | A1 |
20120165203 | Quake et al. | Jun 2012 | A1 |
20120197623 | Homer | Aug 2012 | A1 |
20120203792 | Zhang et al. | Aug 2012 | A1 |
20120208706 | Downing et al. | Aug 2012 | A1 |
20120214172 | Chen et al. | Aug 2012 | A1 |
20120214678 | Rava et al. | Aug 2012 | A1 |
20120220053 | Lee et al. | Aug 2012 | A1 |
20120221249 | Lizardi et al. | Aug 2012 | A1 |
20120221432 | Yuan et al. | Aug 2012 | A1 |
20120237928 | Rava et al. | Sep 2012 | A1 |
20120264121 | Rava et al. | Oct 2012 | A1 |
20120270739 | Rava et al. | Oct 2012 | A1 |
20120271558 | Hur et al. | Oct 2012 | A1 |
20120286244 | Chiu et al. | Nov 2012 | A1 |
20120289408 | Travers et al. | Nov 2012 | A1 |
20120289412 | Seitz et al. | Nov 2012 | A1 |
20120295260 | Pan et al. | Nov 2012 | A1 |
20120330559 | Jiang et al. | Dec 2012 | A1 |
20120330566 | Chaisson | Dec 2012 | A1 |
20130018599 | Peng | Jan 2013 | A1 |
20130029852 | Rava et al. | Jan 2013 | A1 |
20130034546 | Rava et al. | Feb 2013 | A1 |
20130054151 | Kermani et al. | Feb 2013 | A1 |
20130054508 | Kermani et al. | Feb 2013 | A1 |
20130059740 | Drmanac et al. | Mar 2013 | A1 |
20130085681 | Deciu et al. | Apr 2013 | A1 |
20130091126 | Krishnaswami et al. | Apr 2013 | A1 |
20130091176 | Harris et al. | Apr 2013 | A1 |
20130096011 | Rava et al. | Apr 2013 | A1 |
20130096841 | Kermani et al. | Apr 2013 | A1 |
20130103320 | Dzakula et al. | Apr 2013 | A1 |
20130124100 | Drmanac et al. | May 2013 | A1 |
20130137588 | Shendure et al. | May 2013 | A1 |
20130137605 | Shendure et al. | May 2013 | A1 |
20130138355 | Inglis et al. | May 2013 | A1 |
20130138358 | Tang et al. | May 2013 | A1 |
20130140518 | Jain et al. | Jun 2013 | A1 |
20130150253 | Deciu et al. | Jun 2013 | A1 |
20130157870 | Pushkarev et al. | Jun 2013 | A1 |
20130164859 | Johnson et al. | Jun 2013 | A1 |
20130166221 | Inglis et al. | Jun 2013 | A1 |
20130184161 | Kingsmore et al. | Jul 2013 | A1 |
20130190211 | Bustillo et al. | Jul 2013 | A1 |
20130091121 | Bhola et al. | Aug 2013 | A1 |
20130194882 | Ishii et al. | Aug 2013 | A1 |
20130204851 | Bhola et al. | Aug 2013 | A1 |
20130211729 | Sastry-Dent et al. | Aug 2013 | A1 |
20130230909 | Pan et al. | Sep 2013 | A1 |
20130237432 | Li et al. | Sep 2013 | A1 |
20130240378 | Lee et al. | Sep 2013 | A1 |
20130245958 | Forster | Sep 2013 | A1 |
20130251726 | Mascola et al. | Sep 2013 | A1 |
20130261983 | Dzakula et al. | Oct 2013 | A1 |
20130273543 | Gudmundsson et al. | Oct 2013 | A1 |
20130288244 | Deciu et al. | Oct 2013 | A1 |
20130288901 | Kennedy et al. | Oct 2013 | A1 |
20130296175 | Rafnar et al. | Nov 2013 | A1 |
20130297221 | Johnson et al. | Nov 2013 | A1 |
20130304392 | Deciu et al. | Nov 2013 | A1 |
20130307029 | Xu et al. | Nov 2013 | A1 |
20130309666 | Deciu et al. | Nov 2013 | A1 |
20130309678 | Travers et al. | Nov 2013 | A1 |
20130310260 | Kim et al. | Nov 2013 | A1 |
20130311106 | White et al. | Nov 2013 | A1 |
20130316331 | Isakov et al. | Nov 2013 | A1 |
20130316915 | Halpern et al. | Nov 2013 | A1 |
20130316916 | Flusberg et al. | Nov 2013 | A1 |
20130324417 | Kennedy et al. | Dec 2013 | A1 |
20130324419 | Seshagiri | Dec 2013 | A1 |
20130325360 | Deciu et al. | Dec 2013 | A1 |
20130325666 | Carrino et al. | Dec 2013 | A1 |
20130332081 | Reese et al. | Dec 2013 | A1 |
20130338012 | Sulem et al. | Dec 2013 | A1 |
20130338933 | Deciu et al. | Dec 2013 | A1 |
20130338934 | Asadi et al. | Dec 2013 | A1 |
20130345066 | Brinza et al. | Dec 2013 | A1 |
20140024536 | Richards et al. | Jan 2014 | A1 |
20140024541 | Richards et al. | Jan 2014 | A1 |
20140024542 | Richards et al. | Jan 2014 | A1 |
20140025312 | Chin et al. | Jan 2014 | A1 |
20140031240 | Behlke et al. | Jan 2014 | A1 |
20140033125 | Meral | Jan 2014 | A1 |
20140034880 | Blouin et al. | Feb 2014 | A1 |
20140038830 | Srinivasan et al. | Feb 2014 | A1 |
20140045705 | Bustamante et al. | Feb 2014 | A1 |
20140051154 | Hyland et al. | Feb 2014 | A1 |
20140051588 | Drmanac et al. | Feb 2014 | A9 |
20140053294 | Gresshoff | Feb 2014 | A1 |
20140066317 | Talasaz | Mar 2014 | A1 |
20140067830 | Buhler et al. | Mar 2014 | A1 |
20140087961 | Sulem et al. | Mar 2014 | A1 |
20140100792 | Deciu et al. | Apr 2014 | A1 |
20140114582 | Mittelman et al. | Apr 2014 | A1 |
20140121116 | Richards et al. | May 2014 | A1 |
20140122509 | Pantaleoni et al. | May 2014 | A1 |
20140129201 | Kennedy et al. | May 2014 | A1 |
20140134629 | Turner et al. | May 2014 | A1 |
20140148346 | Spormann et al. | May 2014 | A1 |
20140149049 | Chen et al. | May 2014 | A1 |
20140152291 | Afzali-Ardakani et al. | Jun 2014 | A1 |
20140155298 | Von Hoff et al. | Jun 2014 | A1 |
20140156199 | Von Hoff et al. | Jun 2014 | A1 |
20140162278 | Richards et al. | Jun 2014 | A1 |
20140163900 | Erlich et al. | Jun 2014 | A1 |
20140166487 | Lieber et al. | Jun 2014 | A1 |
20140172319 | Von Hoff et al. | Jun 2014 | A1 |
20140173606 | Pantaleoni | Jun 2014 | A1 |
20140193938 | Fife | Jul 2014 | A1 |
20140200166 | Van Rooyen et al. | Jul 2014 | A1 |
20140209982 | Putnam et al. | Jul 2014 | A1 |
20140236490 | McMillen et al. | Aug 2014 | A1 |
20140248692 | Lagace et al. | Sep 2014 | A1 |
20140249052 | Mehmet et al. | Sep 2014 | A1 |
20140260547 | Balandin | Sep 2014 | A1 |
20140264467 | Cheng et al. | Sep 2014 | A1 |
20140264469 | Fife et al. | Sep 2014 | A1 |
20140274774 | Li et al. | Sep 2014 | A1 |
20140297196 | Olson | Oct 2014 | A1 |
20140309944 | McMillen et al. | Oct 2014 | A1 |
20140315199 | Rhodes et al. | Oct 2014 | A1 |
20140363808 | Gu et al. | Dec 2014 | A1 |
20140371109 | McMillen et al. | Dec 2014 | A1 |
20140371110 | Van Rooyen et al. | Dec 2014 | A1 |
20150065353 | Turner et al. | Mar 2015 | A1 |
20150069329 | Jeon et al. | Mar 2015 | A1 |
20150087534 | Gormley et al. | Mar 2015 | A1 |
20150101931 | Garaj et al. | Apr 2015 | A1 |
20150111759 | Ju et al. | Apr 2015 | A1 |
20150123080 | Yamaguchi | May 2015 | A1 |
20150137078 | Guo et al. | May 2015 | A1 |
20150159196 | Travers et al. | Jun 2015 | A1 |
20150159212 | Pantoja et al. | Jun 2015 | A1 |
20150160159 | Afzali-Ardakani et al. | Jun 2015 | A1 |
20150176071 | Fisher et al. | Jun 2015 | A1 |
20150211054 | Kostem et al. | Jul 2015 | A1 |
20150218630 | Sun et al. | Aug 2015 | A1 |
20150225785 | Zhao et al. | Aug 2015 | A1 |
20150232929 | Stephens et al. | Aug 2015 | A1 |
20150233864 | Shen et al. | Aug 2015 | A1 |
20150239947 | Brinkmann et al. | Aug 2015 | A1 |
20150243917 | Kim et al. | Aug 2015 | A1 |
20150259743 | Urgess et al. | Sep 2015 | A1 |
20150302143 | Ma et al. | Oct 2015 | A1 |
20150302144 | Chin et al. | Oct 2015 | A1 |
20150307936 | Goldsmith | Oct 2015 | A1 |
20150307947 | Basu et al. | Oct 2015 | A1 |
20150308977 | Saito et al. | Oct 2015 | A1 |
20150339437 | McMillen et al. | Nov 2015 | A1 |
20150368638 | Steemers et al. | Dec 2015 | A1 |
20160004298 | Mazed et al. | Jan 2016 | A1 |
20160122792 | Peterson et al. | May 2016 | A1 |
20160171153 | Van Rooyen et al. | Jun 2016 | A1 |
20160180019 | Van Rooyen et al. | Jun 2016 | A1 |
20160231251 | Ou et al. | Aug 2016 | A1 |
20160265047 | van Rooyen et al. | Sep 2016 | A1 |
20170018626 | Hoffman et al. | Jan 2017 | A1 |
20170053908 | Hoffman | Feb 2017 | A1 |
20170059514 | Hoffman | Mar 2017 | A1 |
20170102358 | Hoffman | Apr 2017 | A1 |
20170218442 | van Rooyen et al. | Aug 2017 | A1 |
Number | Date | Country |
---|---|---|
102703594 | Oct 2012 | CN |
202854094 | Apr 2013 | CN |
103293209 | Sep 2013 | CN |
104237352 | Dec 2014 | CN |
19813317 | Sep 1999 | DE |
2163646 | Mar 2010 | EP |
2334802 | Jun 2011 | EP |
2535429 | Dec 2012 | EP |
3 235 010 | Oct 2017 | EP |
2004085392 | Mar 2004 | JP |
2010172290 | Aug 2010 | JP |
WO-99049403 | Sep 1999 | WO |
WO-00045322 | Aug 2000 | WO |
WO-0113432 | Feb 2001 | WO |
WO-02090978 | Nov 2002 | WO |
WO-03046220 | Jun 2003 | WO |
WO-2004029298 | Apr 2004 | WO |
WO-2004090100 | Oct 2004 | WO |
WO-2004104161 | Dec 2004 | WO |
WO-2005026925 | Mar 2005 | WO |
WO-2005029059 | Mar 2005 | WO |
WO-2005048134 | May 2005 | WO |
WO-2005090961 | Sep 2005 | WO |
WO-2005113812 | Dec 2005 | WO |
WO-2006015084 | Feb 2006 | WO |
WO-2006019892 | Feb 2006 | WO |
WO-2006096324 | Sep 2006 | WO |
WO-2007064758 | Jun 2007 | WO |
WO-2007076726 | Jul 2007 | WO |
WO-2008022036 | Feb 2008 | WO |
WO-2008098014 | Aug 2008 | WO |
WO-2008127213 | Oct 2008 | WO |
WO-2008143679 | Nov 2008 | WO |
WO-2008156773 | Dec 2008 | WO |
WO-2009035647 | Mar 2009 | WO |
WO-2009120372 | Oct 2009 | WO |
WO-2009143212 | Nov 2009 | WO |
WO-2010003316 | Jan 2010 | WO |
WO-2010027497 | Mar 2010 | WO |
WO-2010036287 | Apr 2010 | WO |
WO-2010036311 | Apr 2010 | WO |
WO-2010051773 | May 2010 | WO |
WO-2010072382 | Jul 2010 | WO |
WO-2010093465 | Aug 2010 | WO |
WO-2010127045 | Nov 2010 | WO |
WO-2010129019 | Nov 2010 | WO |
WO-2010129301 | Nov 2010 | WO |
WO-2010132814 | Nov 2010 | WO |
WO-2011025819 | Mar 2011 | WO |
WO-2011050341 | Apr 2011 | WO |
WO-2011056688 | May 2011 | WO |
WO-2011063210 | May 2011 | WO |
WO-2011071923 | Jun 2011 | WO |
WO-2011082178 | Jul 2011 | WO |
WO-2011090556 | Jul 2011 | WO |
WO-2011090557 | Jul 2011 | WO |
WO-2011090558 | Jul 2011 | WO |
WO-2011090559 | Jul 2011 | WO |
WO-2011091046 | Jul 2011 | WO |
WO-2011091063 | Jul 2011 | WO |
WO-2011095501 | Aug 2011 | WO |
WO-2011137368 | Nov 2011 | WO |
WO-2011139797 | Nov 2011 | WO |
WO-2011143525 | Nov 2011 | WO |
WO-2011145954 | Nov 2011 | WO |
WO-2011145955 | Nov 2011 | WO |
WO-2012006291 | Jan 2012 | WO |
WO-2012029080 | Mar 2012 | WO |
WO-2012051346 | Apr 2012 | WO |
WO-2012058459 | May 2012 | WO |
WO-2012065228 | May 2012 | WO |
WO-2012066582 | May 2012 | WO |
WO-2012085948 | Jun 2012 | WO |
WO-2012092336 | Jul 2012 | WO |
WO-2012092426 | Jul 2012 | WO |
WO-2012095872 | Jul 2012 | WO |
WO-2012101643 | Aug 2012 | WO |
WO-2012123972 | Sep 2012 | WO |
WO-2012142334 | Oct 2012 | WO |
WO-2012142531 | Oct 2012 | WO |
WO-2012168803 | Dec 2012 | WO |
WO-2012168815 | Dec 2012 | WO |
WO-2012170715 | Dec 2012 | WO |
WO-2012172575 | Dec 2012 | WO |
WO-2012177774 | Dec 2012 | WO |
WO-2012177792 | Dec 2012 | WO |
WO-2013043909 | Mar 2013 | WO |
WO-2013052907 | Apr 2013 | WO |
WO-2013052913 | Apr 2013 | WO |
WO-2013055817 | Apr 2013 | WO |
WO-2013058907 | Apr 2013 | WO |
WO-2013062856 | May 2013 | WO |
WO-2013065072 | May 2013 | WO |
WO-2013067167 | May 2013 | WO |
WO-2013080227 | Jun 2013 | WO |
WO-2013088457 | Jun 2013 | WO |
WO-2013109935 | Jul 2013 | WO |
WO-2013109981 | Jul 2013 | WO |
WO-2013119770 | Aug 2013 | WO |
WO-2013123330 | Aug 2013 | WO |
2013128371 | Sep 2013 | WO |
WO-2013148400 | Oct 2013 | WO |
WO-2013166517 | Nov 2013 | WO |
WO-2013177086 | Nov 2013 | WO |
WO-2013177581 | Nov 2013 | WO |
WO-2013184643 | Dec 2013 | WO |
WO-2013192562 | Dec 2013 | WO |
WO-2014008447 | Jan 2014 | WO |
WO-2014012051 | Jan 2014 | WO |
WO-2014014497 | Jan 2014 | WO |
WO-2014014498 | Jan 2014 | WO |
WO-2014014950 | Jan 2014 | WO |
WO-2014015084 | Jan 2014 | WO |
WO-2014015319 | Jan 2014 | WO |
WO-2014018093 | Jan 2014 | WO |
WO-2014024041 | Feb 2014 | WO |
WO-2014024598 | Feb 2014 | WO |
WO-2014026168 | Feb 2014 | WO |
WO-2014036488 | Mar 2014 | WO |
WO-2014039556 | Mar 2014 | WO |
WO-2014041380 | Mar 2014 | WO |
2014060305 | Apr 2014 | WO |
WO-2014052909 | Apr 2014 | WO |
WO-2014055774 | Apr 2014 | WO |
2014074246 | May 2014 | WO |
WO-2014071070 | May 2014 | WO |
WO-2014071279 | May 2014 | WO |
WO-2014078739 | May 2014 | WO |
WO-2014089241 | Jun 2014 | WO |
WO-2014112199 | Jul 2014 | WO |
WO-2014142850 | Sep 2014 | WO |
WO-2014153188 | Sep 2014 | WO |
WO-2014166535 | Oct 2014 | WO |
WO-2014171969 | Oct 2014 | WO |
WO-2014172046 | Oct 2014 | WO |
WO-2014176524 | Oct 2014 | WO |
WO-2015033229 | Mar 2015 | WO |
WO-2015123444 | Aug 2015 | WO |
WO-2016205253 | Dec 2016 | WO |
Entry |
---|
Definition of “Well”, http://www.merriam-webster.com (2016). |
International Search Report for PCT Application No. PCT/US2015/064848, dated Mar. 31, 2016. |
Basu et al., Recent Advances in Carbon Nanotubes Based Biosensors, Sensors, 8:1-x manuscripts, downloaded from: http://www.mdpi.org/sensors/accepted/sensors-util-24-21-malhorta-in-PRE-PUBLISHED-VERSION-0422.pdf (Jan. 31, 2008). |
Cooper et al., Experimental Review of Graphene, ISRN Condensed Matter Physics 2012: Art. ID 501686, 56 pages. (2012). |
DeVolder et al., Carbon Nanotubes: Present and Future Commercial Applications, Science, 339: 535-539 (Feb. 1, 2013). |
Fakih et al., Large area graphene ion sensitive field effect transistors with tantalum pentoxide sensing layers for pH measurement at the Nernstian limit, Applied Physics Letters 105: 083101 (Aug. 25, 2014). |
Gao et al., The new age of carbon nanotubes: An updated review of functionalized carbon nanotubes in electrochemical sensors, Nanoscale 4:1948 (2012). |
Green et al., Interactions of DNA with graphene and sensing applications of graphene field-effect transistor devices: A review, Analytica Chimica Acta 853:127-142 (2015). |
Kim, Lecture Notes, 2.76/2.760 Multiscale Systems Design & Manufacturing, downloaded from: http://ocw.mit.edu/courses/mechanical-engineering/2-76-multi-scale-system-design-fall-2004/lecture-notes/lecture_15.pdf (Fall 2004). |
Park et al., High-density integration of carbon nanotubes via chemical self-assembly, Nature Nanotechnology 7:787-791 (2012). |
Schwierz, Frank; Graphene Transistors, Nature Nanotechnology 5:487-496 (May 30, 2010). |
Tulevski et al., Toward High-Performance Digital Logic Technology with Carbon Nanotubes, ACS Nano 8(9):8730-8745 (Aug. 21, 2014). |
Zhan et al., Graphene Field-Effect Transistor and Its Application for Electronic Sensing, Small 10(20):4042-4065 (Aug. 29, 2014). |
Cheng, Zengguang et al. “Sensitivity Limits and Scaling of Bioelectronic Graphene Transducers.”, Nano Letters, (2013), pp. 2902-2907, 13(6), ACS Publications. |
Cheng, Zengguang et al. “Supporting Information for: Sensitivity Limits and Scaling of Bioelectronic Graphene Transducers.”, (2013), 26 pages, pubs.acs.org. [retrieved from the Internet on Nov. 7, 2017]. |
Cheng, Zengguang et al. “Suspended Graphene Sensors with Improved Signal and Reduced Noise.” Nano Letters, (2010), pp. 1864-1868, 10(5), pubs.acs.org. |
Kim, Kihyun et al. “Electrical and pH Sensing Characteristics of Si Nanowire-Based Suspended FET Biosensors.” Proceedings of the 14th IEEE, International Conference on Nanotechnology, IEEE, (Aug. 18-21, 2014), pp. 768-771. |
Kim, Kihyun et al. “Suspended honeycomb nanowire ISFETs for improved stiction-free performance.” Nanotechnology,(2014), pp. 345-501 (7 pages), 25(34), IOP Publishing, Bristol, GB. |
Wang, Bei et al. “Oxide-on-graphene field effect bio-ready sensors.” Nano Research, (2014), 7(9):pp. 1263-1270. Tsinghua University Press, CN. |
Xu et al. “Electrophoretic and field-effect graphene for all-electrical DNA array technology.” Nature Communications, (2014) 5:4866. 9 pages. |
Liu, Song and Xuefeng Guo, “Carbon nanomaterials field-effect-transistor-based biosensors.” NPG Asia Materials (2012), pp. 1-10, 4, e23; doi: 10.1038/sm.2012.42: published online Aug. 17, 2012. |
Baraket, Mira et al. (2008) “Aminated graphene for DNA attachment produced via plasma functionalization”, Applied Physics Letters, A I P Publishing LLC, US, vol. 100, No. 23, Jun. 4, 2012 (Jun. 4, 2012) pp. 233123-233123-4, XP012156487, ISSN: 0003-6951, DOI: 10.1063/1.4711771 [retrieved on Jun. 8, 2012]. |
Schwierz, Frank, J. Pezoldt and R. Granzner, “Two-dimensional materials and their prospect in transistor electonics.” Nanoscale, 2015, 7, pp. 8261-8283. |
Number | Date | Country | |
---|---|---|---|
20160178569 A1 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
62206228 | Aug 2015 | US | |
62199987 | Aug 2015 | US | |
62130594 | Mar 2015 | US | |
62094016 | Dec 2014 | US |